Guardian Capital (Canada)’s Vertex Pharmaceuticals VRTX Stock Holding History

Guardian Capital (Canada)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,153	Closed	-$509K	–	168
2020 Q4	$509K	Buy	2,153 +220	+11%	+$50.5K	0.01%	146
2020 Q3	$526K	Buy	1,933 +200	+12%	+$55.2K	0.01%	144
2020 Q2	$503K	Buy	+1,733	New	+$470K	0.01%	133
2019 Q4	–	Sell	-3,156	Closed	-$535K	–	167
2019 Q3	$535K	Buy	3,156 +1,355	+75%	+$240K	0.01%	130
2019 Q2	$330K	Sell	1,801 -597	-25%	-$104K	0.01%	157
2019 Q1	$441K	Sell	2,398 -361	-13%	-$66.7K	0.01%	139
2018 Q4	$457K	Sell	2,759 -600	-18%	-$104K	0.01%	133
2018 Q3	$647K	Sell	3,359 -657	-16%	-$117K	0.01%	122
2018 Q2	$683K	Buy	+4,016	New	+$623K	0.01%	128

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Guardian Capital (Canada)'s VRTX Position: Q1 2021 in Review

Guardian Capital (Canada) sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 2,153 shares — an estimated $509K sold.

Guardian Capital (Canada) first reported a position in VRTX in Q2 2018 and held it in 9 quarters. The position peaked at $683K in Q2 2018. 999 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

Guardian Capital (Canada) reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Guardian Capital (Canada) sold 2,153 Vertex Pharmaceuticals shares in Q1 2021, an estimated $509K.
Guardian Capital (Canada) first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 9 quarters.
Guardian Capital (Canada)'s Vertex Pharmaceuticals position peaked at $683K in Q2 2018.
999 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Guardian Capital (Canada)'s 13F filing for Q1 2021, filed 17 May 2021.